GeoVax Announces Addition to Its Board of Directors
September 01, 2022 09:00 ET
|
GeoVax, Inc.
Nicole Lemerond, CFA, Brings Healthcare Finance Expertise to the GeoVax Board ATLANTA, GA, Sept. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax Announces Key Staff Appointments
March 07, 2022 09:00 ET
|
GeoVax, Inc.
Operational Resources Strengthened in Support of Ongoing Phase 2 Clinical Trials for COVID-19 and Advanced Head & Neck Cancer ATLANTA, GA, March 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –...
GeoVax Announces Issuance of Hepatitis B Vaccine Patent
July 07, 2021 09:00 ET
|
GeoVax, Inc.
Vaccine Would Address Therapeutic Medical Need of Over 250 Million Worldwide ATLANTA, GA, July 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the...
Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021
March 01, 2021 09:00 ET
|
GeoVax, Inc.
Meet with GeoVax CEO David Dodd & CFO Mark Reynolds who will Deliver a Presentation Titled “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” ATLANTA,...
GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development
October 26, 2020 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and...
GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update
August 10, 2020 09:00 ET
|
GeoVax, Inc.
Company Demonstrated Progress on COVID-19 Vaccine Development;Continued Progress in Other Infectious Disease and Immuno-Oncology Programs ATLANTA, GA, Aug. 10, 2020 (GLOBE NEWSWIRE) -- via...
GeoVax Announces Closing of $1 Million Private Placement
June 29, 2020 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, June 29, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases...
GeoVax Announces Reverse Stock Split
January 23, 2020 09:00 ET
|
GeoVax, Inc.
1:2000 Reverse Split Effective January 24, 2020;Ticker Symbol Changed to GOVXD for 20 Days ATLANTA, GA, Jan. 23, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTC: GOVX) today...
GeoVax Announces 100% Protection Data from Marburg Virus Vaccine Study
July 29, 2019 09:00 ET
|
GeoVax, Inc.
Study Data Adds to Similar Efficacy Previously Reported for GeoVax’s Ebola and Lassa Fever Vaccines ATLANTA, GA, July 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB:...
GeoVax Comments on Age-Associated HIV Infection Trends in the U.S.
September 24, 2018 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Sept. 24, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today commented on recent age-associated HIV...